Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2006

Curalogic Signs Up for SAFC’s Chemical Development Services

  • SAFC will provide protein isolation, extraction, and purification services to Curalogic in connection with the development of products focused on allergic rhinitis.

    Curalogic seeks to develop pharmaceuticals that are just as effective as injection immunotherapy. Key products include a ragweed pollen extract that has just completed Phase II trials, a grass pollen extract and cat extract currently in Phase II, and a house dust mite extract that is in preclinical trials.

    SAFC Pharma chemists working at the existing St. Louis protein purification and extraction facility will begin initial phases of the project. These phases explore development of grass and house dust mite compounds to determine a suitable process for producing sufficient quantities of cGMP material for future clinical trials and commercial launch of these products. Subsequent phases of the Curalogic project will be transferred into the SAFC plant after its scheduled completion in April 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »